clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

References related to abnormalities published in Antimicrob. Agents Chemother.


PMIDJournalPublished DateAuthorTitle
9559810Antimicrob. Agents Chemother.1998Cheng KL et al.Effect of grapefruit juice on clarithromycin pharmacokinetics.
9517944Antimicrob. Agents Chemother.1998Hafner R et al.Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.
9517960Antimicrob. Agents Chemother.1998Fattorini L et al.Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice.
10223952Antimicrob. Agents Chemother.1999Fish DN and Abraham EPharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.
9687409Antimicrob. Agents Chemother.1998Portaels F et al.In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.
9593154Antimicrob. Agents Chemother.1998Sörberg M et al.Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.
10049289Antimicrob. Agents Chemother.1999Wang G et al.Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori.
11181351Antimicrob. Agents Chemother.2001Wang G et al.Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori.
11709323Antimicrob. Agents Chemother.2001Endo H et al.Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats.
11408237Antimicrob. Agents Chemother.2001Kalach N et al.Clarithromycin resistance and eradication of Helicobacter pylori in children.
12121899Antimicrob. Agents Chemother.2002Fong IW et al.Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model.
11959578Antimicrob. Agents Chemother.2002Tessier PR et al.Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia.
12019085Antimicrob. Agents Chemother.2002Finch R et al.Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
12019131Antimicrob. Agents Chemother.2002Prazeres Magalhães P et al.Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil.
12234844Antimicrob. Agents Chemother.2002Dega H et al.Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
12234874Antimicrob. Agents Chemother.2002Endo H et al.Effects of clarithromycin and amoxicillin on gastric emptying in rats.
12821476Antimicrob. Agents Chemother.2003van Zanten SJ et al.Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.
12709330Antimicrob. Agents Chemother.2003Hardy RD et al.Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.
12435719Antimicrob. Agents Chemother.2002Noreddin AM et al.Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations.
11120942Antimicrob. Agents Chemother.2001Ichiyama T et al.Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.
10991834Antimicrob. Agents Chemother.2000Bermudez LE et al.Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.
10991870Antimicrob. Agents Chemother.2000Rastogi N et al.In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4.
10898693Antimicrob. Agents Chemother.2000Jordan MK et al.Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.
10898707Antimicrob. Agents Chemother.2000Kato M et al.Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan.
9756789Antimicrob. Agents Chemother.1998Gikas A et al.In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.
9797242Antimicrob. Agents Chemother.1998Horgen L et al.Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium.
9660986Antimicrob. Agents Chemother.1998Amsden GW et al.Oral cimetidine prolongs clarithromycin absorption.
11600387Antimicrob. Agents Chemother.2001Lounis N et al.Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.
11600400Antimicrob. Agents Chemother.2001Gikas A et al.In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.
14506021Antimicrob. Agents Chemother.2003Best LM et al.Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.
15328128Antimicrob. Agents Chemother.2004Khan R et al.T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh.
14693524Antimicrob. Agents Chemother.2004Giamarellos-Bourboulis EJ et al.Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
21189342Antimicrob. Agents Chemother.2011Liou JM et al.Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.
19451301Antimicrob. Agents Chemother.2009Wakabayashi H et al.Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia.
19414584Antimicrob. Agents Chemother.2009Abduljalil K et al.Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.
19949056Antimicrob. Agents Chemother.2010Nakamura S et al.Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.
20585115Antimicrob. Agents Chemother.2010Alffenaar JW et al.Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.
22290969Antimicrob. Agents Chemother.2012English ML et al.Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.
17664316Antimicrob. Agents Chemother.2007Ji B et al.Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
17606673Antimicrob. Agents Chemother.2007Traunmüller F et al.Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.
17709469Antimicrob. Agents Chemother.2007Kohno Y et al.In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
18391038Antimicrob. Agents Chemother.2008Ji B et al.Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
18378709Antimicrob. Agents Chemother.2008Greendyke R and Byrd TFDifferential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.
15793150Antimicrob. Agents Chemother.2005Lee JH et al.Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults.
15561829Antimicrob. Agents Chemother.2004Watanabe K et al.Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
15561865Antimicrob. Agents Chemother.2004Kim JM et al.Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea.
15504839Antimicrob. Agents Chemother.2004Berg HF et al.Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study.
16048933Antimicrob. Agents Chemother.2005Mathis A et al.Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis.
16048962Antimicrob. Agents Chemother.2005Dai G et al.Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.
15917538Antimicrob. Agents Chemother.2005Bakker-Woudenberg IA et al.Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.
15917564Antimicrob. Agents Chemother.2005Kim YC et al.Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.
16569825Antimicrob. Agents Chemother.2006Dean NC et al.Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
16436754Antimicrob. Agents Chemother.2006Leuthner KD et al.Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae.
16641444Antimicrob. Agents Chemother.2006Shinkai M et al.Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression.
16801446Antimicrob. Agents Chemother.2006Andini N and Nash KAIntrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible.
18779356Antimicrob. Agents Chemother.2008Cirioni O et al.Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis.
22564837Antimicrob. Agents Chemother.2012Spyridaki A et al.Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study.
22687518Antimicrob. Agents Chemother.2012Goswami S et al.Anti-Helicobacter pylori potential of artemisinin and its derivatives.
23478956Antimicrob. Agents Chemother.2013Koh WJ et al.Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
23689722Antimicrob. Agents Chemother.2013Bolhuis MS et al.Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.
23545534Antimicrob. Agents Chemother.2013Alhajlan M et al.Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.
23183432Antimicrob. Agents Chemother.2013Koh WJ et al.Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only.
24323473Antimicrob. Agents Chemother.2014Phillips RO et al.Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.